Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Endlyz Therapeutics
London, United Kingdompitchbook.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Endlyz Therapeutics has emerged from stealth with a pipeline of small-molecule modulators targeting ATP13A2 and ATP10B to restore lysosomal function in Parkinson’s disease and other neurodegenerative conditions. The lead program aims to enter IND-enabling studies in 2025, supported by a $2.2M grant from the Michael J. Fox Foundation for biomarker discovery bridging preclinical and clinical development[1][3].
No clinical results have been reported yet.
The company’s approach seeks to slow or halt disease progression rather than only address symptoms.
Collaboration with KU Leuven provides access to advanced lysosomal transporter research and drug design expertise[6].
Pipeline breadth:
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
Beyond the preview
Go deeper on Endlyz Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endlyz Therapeutics.